Patents Represented by Attorney Ron Levy
  • Patent number: 6096753
    Abstract: Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: August 1, 2000
    Assignee: Amgen Inc.
    Inventors: Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo
  • Patent number: 6022884
    Abstract: Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: February 8, 2000
    Assignee: Amgen Inc.
    Inventors: Nathan B. Mantlo, Stephen T. Schlachter, John A. Josey
  • Patent number: 5989538
    Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: November 23, 1999
    Assignee: Amgen Inc.
    Inventor: Steven G. Elliott
  • Patent number: 5929032
    Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Patent number: 5914251
    Abstract: Polypeptide growth factors, termed PDFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 22, 1999
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Patent number: 5861315
    Abstract: Stem cell factor in combination with soluble interleukin-6 receptor, interleukin-6, for gp130 signaling, supports the proliferation, differentiation and terminal maturation of blood cells from normal human hematopoietic multipotential cells.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: January 19, 1999
    Assignees: Amgen Inc., Tosoh Corporation
    Inventor: Tatsutoshi Nakahata
  • Patent number: 5830857
    Abstract: A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Antoine Depaulis, Paul Feltz, Yves Larmet, Christian Marescaux, Hiroyuki Nawa
  • Patent number: 5817784
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: October 6, 1998
    Assignees: Amgen Inc., Yeda Research and Development Co., Ltd.
    Inventors: Lars Eyde Theill, Gregory Scott Naeve, Yoav Citri, deceased
  • Patent number: 5770577
    Abstract: Derivatives of the neurotrophic factors BDNF and NT-3 have been prepared by attachment of these polypeptides to a water soluble polymer, for instance, polyethylene glycol.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 23, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf Boris Kinstler, Qiao Yan
  • Patent number: 5770203
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: June 23, 1998
    Assignees: Amgen Inc., University of Southern California
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Patent number: 5747639
    Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: May 5, 1998
    Assignee: Amgen Boulder Inc.
    Inventor: James Ervin Seely
  • Patent number: 5714667
    Abstract: Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: February 3, 1998
    Assignee: Amgen Canada Inc.
    Inventors: Paul David Waterhouse, Tak Wah Mak
  • Patent number: 5661125
    Abstract: The invention is to stable compositions of erythropoietin that contain an antimicrobial preservative thereby providing a multi-dose formulation. Preservatives useful in the pharmaceutical compositions of the present invention include benzyl alcohol, parabens, phenol and mixtures thereof. Other additives, including buffers may be included in the composition.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: August 26, 1997
    Assignee: AMGEN, Inc.
    Inventor: Thomas Wayne Strickland
  • Patent number: 5639658
    Abstract: Provided are methods for fed batch fermentation of cells to produce a compound of interest. Also provided are methods of preparing a compound of interest.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: June 17, 1997
    Assignee: Amgen Inc.
    Inventors: Kenneth Mitchell Drobish, Vasuki Nagaraju Satyagal, Raj Kumar Sachdev